127 results about "Inflammatory dermatosis" patented technology

A topical spray or foam, methods of making the formulation, and methods of use thereof, has been developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, anti-pruritic agents to minimize itching, and skin protective compounds may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein at least one of the drugs is bound to an ion-exchange resin. The use of binding resins, such as ion-exchange resins, allows drugs with incompatible solvent requirements to be prepared in a single-phase formulation.

Methods are disclosed for treating an inflammatory skin condition in a subject. The methods comprise administering to a subject an HMGB antagonist, such as a high mobility group box (HMGB) A box or a biologically active fragment thereof, an antibody to HMGB or an antigen-binding fragment thereof, an HMGB small molecule antagonist, an antibody to TLR2 or an antigen-binding fragment thereof, a soluble TLR2 polypeptide, an antibody to RAGE or an antigen-binding fragment thereof, a soluble RAGE polypeptide and a RAGE small molecule antagonist.

The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents; (2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia; (3) it is a treatment of inflammatory conditions of mucosae; (4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin.

This application relates to a stable pharmaceutical composition and methods for the cleaning of skin to facilitate the prevention, treatment, and management of skin conditions, such as seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, impetigo and other inflammatory skin conditions, and the like, including a sufficient amount of an acidic component of a hydroxyacid or tannic acid, or a pharmaceutically acceptable salt thereof, to exfoliate a portion of the skin, a sufficient amount of stabilized hydrogen peroxide to facilitate cleansing of the skin without substantial irritation thereof, and an antimicrobial agent including at least one of an antibacterial agent, antimicrobial agent, antiviral agent, anthelmintic, or a combination thereof, in an amount sufficient to inhibit or reduce microorganisms on the skin.

Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.

Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.

Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatologic disorders in which the amphoteric compositions and the polymeric compounds may be useful include dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, kyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging, and skin requiring cleansers.

Methods and composition for treating or preventing an inflammatory dermatological disease or condition, such as psoriasis, in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of a composition comprising at least one indigo naturalis composition, beberine and a pharmaceutically acceptable carrier.

Provided are methods and topical pharmaceutical formulations for the treatment of inflammatory dermatoses. The invention involves the topical administration of a pharmacologically active base in a formulation having a pH of about 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations are particularly suited to the treatment of acne vulgaris.

The invention provides a method and composition for treating dermatoses by topical application of a composition containing an antihistamine, an NSAID and optionally a botanical medicinal compound. The compositions are useful for skin conditions such as inflammatory skin conditions, including eczema, atopic dermatitis, non-allergic dermatitis, psoriasis and rosacea, or any inflammation of the skin.

The embodiment of the invention discloses a recognition method and system based on dermatopathology images. A multi-task learning deep learning technology is adopted, three tasks of tissue area segment, pathological feature extraction and disease sorting recognition are sequentially completed, three deep learning models of tissue area segment model, pathological feature extraction model and disease sorting recognition model are correspondingly established, systematic modeling is conducted following a clinical structural analysis method of a doctor, and controllable key points and indicators ofartificial intelligent in pathological diagnosis are achieved; the tissue area segment and pathological feature extraction models are characterized in that training and learning are conducted takingpixel as the smallest unit, the scale of the needed sample number is controllable, the restriction of a large number of samples is broken through, the ultimate learning result is used for processing the pathological recognition of various kinds of inflammatory dermatosis, the dermatosis diagnosis and recognition efficiency in China is greatly improved, the automated technology level is high, and alarge amount of labor force and material resource are saved.

The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatogical conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

The invention relates to a Chinese medicinal composition for treating eczema and a preparation thereof. The eczema is common inflammatory dermatosis caused by various internal and external factors of epidermis and dermis superficial layers. At present, in western medicine treatment, antihistamine medicaments for oral administration and corticoid medicaments are used mostly to inhibit temporarily, the treatment effect is poor, the eczema is not treated radically and the side effect is large. Thus, the eczema is treated mainly by Chinese medicaments. The Chinese medicinal composition of the invention is prepared from Chinese patent medicaments of lightyellow sophora root, astragalus, large-headed atractylodes rhizome, rhizoma smilacis glabrae and the like which are used for clearing heat and drying damp and taken as main materials, and cortex moutan for clearing heat and cooling blood and activating blood and resolving stasis, dictamnus bark for clearing away heat and toxic materials and expelling wind-damp, red paeony root for clearing heat and cooling blood and promoting blood circulation and removing blood stasis and raw liquoric root for tonifying the spleen and qi and clearing away heat and toxic materials, and the medicaments are processed into an oral administration preparation for invigorating the spleen and promoting diuresis and promoting blood circulation and removing blood stasis. The decades of clinical application and experiments prove that the Chinese medicinal composition has the excellent effect on the treatment of the eczema and the effect of relieving constipation, and has the effects of improving gastrointestinal tracts obviously during the administration of patients.

The present invention provides a topical preparation for treating patients with skin inflammatory disease. The topical preparation contains an antibody to interleukin-8 (IL-8) and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody, a polyclonal antibody, an antibody fragment, or a combination thereof. The monoclonal antibody is a murine anti-human IL-8 monoclonal antibody produced in a hybridoma. The polyclonal antibody is a chicken anti-human polyclonal antibody, which is prepared by immunizing a chicken with human IL-8, collecting eggs from the immunized chicken, and purifying the IgY from the eggs. The topical preparation is effective in topically treating inflammatory skin diseases. The present invention also provides a method for treating patients with skin inflammatory disease, which is by topically applying an effective amount of the topical preparation onto patients with skin inflammatory disease.

The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory conditions.

The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.

The invention relates to a traditional Chinese medicinal composition for treating inflammatory dermatosis and a preparation thereof. Inflammatory dermatosis is a common skin disease in life, including ringworm of the body, eczema, acne, dermatitis and the like. The traditional Chinese medicinal composition provided by the invention is composed of xanthium, common cnidium fruit, cortex of Chinese dittany root, rhizoma atractylodis, Sophora flavescens, rheum officinale, phellodendron and broom cypress fruit, and is made into an external-use preparation. It proves through experiments that the product has a good effect of treating inflammatory dermatosis, is safe and nontoxic, has no side effect, and can be used in treating infant inflammatory dermatosis.

Presented herein inter alia are compositions, methods, and kits for treating an inflammatory skin disorder using a histamine antagonist. In certain embodiments, the compositions, methods, and kits are for treating urticaria and its symptoms. In certain embodiments, the composition, methods, and kits include a topical pharmaceutical preparation with an effective amount of alcaftadine as an active agent.